Perform Another (Advanced) Search

1.  Newly Approved Drug Therapies (372) Tobi, PathoGenesis,
...Tobi Company: PathoGenesis Approval Status: Approved December 1997 Treatment Area: cystic fibrosis General Information Tobi (tobramycin) has been approved as an inhaled antibiotic for the treatment of cystic fibrosis. It is ...
View Page

2.  Newly Approved Drug Therapies (117) Zosyn (sterile piperacillin sodium/tazobactam sodium), Wyeth,
...300 subjects with nosocomial pneumonia, the rate of clinical cure or improvement for Zosyn plus tobramycin was 74%, compared with 50% for ceftazidime plus tobramycin (p is less than .01). The Zosyn regimen eradicated 78% of all pathogens, compared with ...
View Page

3.  CenterWatch: New Medical Therapies in Disease Category (53), Cystic Fibrosis
...a phase I safety, pharmacokinetic and delivery-time trial of their inhalable powder formulation of tobramycin (TPI) , for the treatment of Pseudomonas aeruginosa (Pa) respiratory infections in patients with cystic fibrosis ...
...that TPI offered preliminary evidence of non-inferior efficacy, compared to other approved formulations of tobramycin, and offered a drastically reduced treatment burden over these current therapies. The drug was also ...
View Page

4.  CenterWatch: New Medical Therapies in Disease Category (227), Eye Disorders/Infections
...efficacy endpoint, producing statistical non-inferiority in clinical resolution rate relative to approved treatment with tobramycin (80% vs. 78%, respectively) over fewer total doses. Adverse events occurred at similar rates between ...
...daily for 2 days, then once daily for 3 days), or an ophthalmic formulation of tobramycin (four times daily for 5 days). May 9, 2005 Genaera issued interim results of a ...
View Page